Pre-made Ponezumab benchmark antibody ( Whole mAb, anti-APP therapeutic antibody, Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ponezumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-450-1mg	1mg	3090
GMP-Bios-ab-450-10mg	10mg	Inquiry
GMP-Bios-ab-450-100mg	100mg	Inquiry
GMP-Bios-ab-450-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ponezumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
INN Name	Ponezumab
Target	APP
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	3u0t:BA:DC
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Rinat Neuroscience;Pfizer
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Alzheimer's disease;Cerebral amyloid angiopathy
Development Tech	na